Cost consequences of HIV-associated lipoatrophy.

about

Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data

P2860

Q33891656-083E7367-277E-4796-9302-2BC16B2F3A40

P2860

Cost consequences of HIV-associated lipoatrophy.

Item

http://www.wikidata.org/entity/Q53508863

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Cost consequences of HIV-associated lipoatrophy.

@en

Cost consequences of HIV-associated lipoatrophy.

@nl

type

Item

label

Cost consequences of HIV-associated lipoatrophy.

@en

Cost consequences of HIV-associated lipoatrophy.

@nl

prefLabel

Cost consequences of HIV-associated lipoatrophy.

@en

Cost consequences of HIV-associated lipoatrophy.

@nl

P1476

Cost consequences of HIV-associated lipoatrophy.

@en

P2093

A Shewade

http://www.w3.org/2001/XMLSchema#string

J Hornberger

http://www.w3.org/2001/XMLSchema#string

M R Loutfy

http://www.w3.org/2001/XMLSchema#string

R Rajagopalan

http://www.w3.org/2001/XMLSchema#string

P2860

Correction options for lipoatrophy in HIV-infected patients.

Lipodystrophy syndrome in patients with HIV infection: quality of life issues.

A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals

Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy.

Interventions for managing antiretroviral therapy-associated lipoatrophy.

HIV facial lipoatrophy: causes and treatment options.

A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy.

High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.

Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

P304

664-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09540120802511851

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24429674

http://www.w3.org/2001/XMLSchema#string

P698

19444676

http://www.w3.org/2001/XMLSchema#string

Cost consequences of HIV-associated lipoatrophy.

about

P2860

P2860

Cost consequences of HIV-associated lipoatrophy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698